Publications

Select publications about our development pipeline of innovative therapeutics

These articles or posters contain information about investigational compounds that are not approved by the FDA. The safety and efficacy of these products have not been established.

Clinical Program: Human Studies

Bakker A, Albert MS, Krauss GL, Speck CL, Gallagher M (2015) Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. NeuroImage: Clinical 7: 688-698.
View the article

 

Haberman, R.P., Branch, A. & Gallagher, M. (2017) Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer’s Disease. Neurotherapeutics. doi:10.1007/s13311-017-0541-z.
View the article

 

Mohs R, Rosenzweig-Lipson S, Gallagher M, Albert M (2016) Phase 3 Clinical Trial in MCI due to AD Targeting Hippocampal Hyperactivity 9th International Conference on Clinical Trials for Alzheimer’s Disease, San Diego, CA.
CTAD Mohs Poster

 

Rosenblum M, Colantuoni E, Steingrimsson J, Bakker A, Gallagher M (2016) Improving Precision and Power by Adjusting for Prognostic Baseline Variables in Alzheimer’s Disease Clinical Trials 9th International Conference on Clinical Trials for Alzheimer’s Disease, San Diego, CA.
CTAD Colantuoni Poster

 

Rosenzweig-Lipson S, Mulcahy S, Payie K, Bullock S,  Melsopp E, James J,  Gallagher M (2015) Pharmacokinetic Profile of a Novel Low Dose Extended Release Formulation of AGB101 (Levetiracetam). 8th Clinical Trials on Alzheimer’s Disease, Barcelona, Spain.
CTAD poster 2015

 

Tran T, Speck C, Pisupati A, Gallagher M, Bakker A (2016) Increased hippocampal activation in ApoE-4 carriers and non-carriers with amnestic mild cognitive impairment. NeuroImage: Clinical 13:237-245.

View the article

 

Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE (2010) High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment. Neuroimage 51: 1242-1252.

View the article

 

Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M (2012) Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74: 467-474.

View the article

 

Putcha D, Brickhouse M, O’Keefe K, Sullivan C, Rentz D, Marshall G, Dickerson B, Sperling R (2011) Hippocampal hyperactivation associated with cortical thinning in Alzheimer’s disease signature regions in non-demented elderly adults. The Journal of Neuroscience 31: 17680-17688.

View the article

 

Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A (2013) Integrative genomics identifies APOE ε4 effectors in Alzheimer’s disease. Nature 500: 45-50.

View the article

 

Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW (2014) Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer’s disease. Neurobiology of Aging 35: 1961-1972.

View the article

 


Preclinical Program: Animal Models

Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M (2010) Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology 35: 1016-1025.

View the article

 

Busche MA, Chen X, Henning HA, Reichwald J, Staufenbield M, Sakmann B, Konnerth A (2012) Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences USA 109: 8740-8745.

View the article

 

Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proceedings of the National Academy of Sciences USA 109: E2 895–E2 903.

View the article

 

Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L (2013) Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β. Nature Neuroscience 16: 613-621.

View the article


Discovery GABA Program

Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA (2011) A novel a5GABAAR-Positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of Schizophrenia. Neuropsychopharmacology 36: 1903-1911.

View the article

 

Koh MT, Rosenzweig-Lipson S, Gallagher M (2013) Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology 64: 145-152.

View the article